Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 12.72 |
---|---|
High | 13.14 |
Low | 12.55 |
Bid | 12.36 |
Offer | 13.50 |
Previous close | 12.52 |
Average volume | 765.95k |
---|---|
Shares outstanding | 71.05m |
Free float | 65.96m |
P/E (TTM) | -- |
Market cap | 889.51m USD |
EPS (TTM) | -1.52 USD |
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
- Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference
- Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)
- Zymeworks Announces Participation in Upcoming Investor Conferences
- Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock
- Zymeworks Provides Corporate Update and Reports Second Quarter 2024 Financial Results
- Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer
- Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate
- Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024
- Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
- Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
More ▼